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Background: Acute Myeloid Leukaemia (AML) is a form of cancer that is associated with 
low survival rates, and where the current treatment is impaired by low tolerance and severe 
side-effects. Thus, novel treatments are needed to increase the life-expectancy of AML-
patients. The phenazine 5,10-dioxide compound, iodinin, has shown promising cytotoxic 
effects against AML cell lines in previous research. Iodinin itself has low solubility in 
aqueous media, and it was necessary to develop analogues with improved drug properties, 
which can be tested in animal models for toxicity and efficacy. 
Methods: The cytotoxicity of the analogues IM 5, IM 20, IM 56 and IM 69 was investigated 
by performing viability assays on OCI-AML-3 and MOLM-13 AML cell lines and comparing 
the results to previously obtained results for the normal cell lines rat kidney epithelial (NRK) 
and cardiac myeloblast (H9c2). The generation of reactive oxygen species (ROS), by a 
fluorescent reporter (DCF), was also investigated for MOLM-13 and H9c2 cells. Furthermore, 
key factors in ROS signalling were investigated by western blot. The physiochemical 
properties were studied by a screening assay for membrane permeability and in silico-
prediction of properties important for permeability and biodistribution and linked to the 
biological activity of the analogues.  
Results: The analogue IM 56 showed increased cytotoxicity towards AML cell lines 
compared to the parent compound IM 5. It was also less toxic towards normal cell lines 
compared to the most frequently used AML drug, the anthracycline Daunorubicin. The 
difference in biological activities of the analogues is supported by their difference in 
membrane permeability. The analogues increase the generation of ROS in MOLM-13 cells. 
Except for the analogue IM 20, no such increase could be detected in H9c2 cells.  
Conclusion: The analogue IM 56 was chosen for further drug development, due to its 
enhanced effect against AML cell lines relative to normal cell lines. It increases cell death in 
MOLM-13 cells, most likely due to generation of ROS. IM 56 is thus a promising candidate 





AB – antibody 
AML – acute myeloid leukaemia 
AMPK – AMP-activated protein kinase 
BSA- bovine serum albumin 
CR – complete remission 
Cpd. - compound 
DDS – direct detect spectrophotometer  
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1.1 Cancer and Acute Myeloid Leukaemia 
 
Cancer is a term used to describe related malignancies, which all have in common 
uncontrolled growth of cells. A malign cancer can utilise the blood vessels or lymphatic 
system to invade other parts of the body, a process called metastasis. At this stage, the cancer 
has often reached a life-threatening stage, and therapeutic intervention, like surgery, radiation, 
or chemotherapy, must be initiated (1).  
Acute Myeloid Leukaemia (AML) is a form of cancer where the myeloid cells in the bone 
marrow are arrested at an undifferentiated state but continue proliferate. This causes 
accumulation of immature cells, which will take up space from the normal cells, and disturb 
the production of normal cells. Eventually, the AML cells will invade into the blood stream 
(2). The classical diagnostic feature is >20% undifferentiated myeloid blasts in a bone marrow 
sample (3). Numbers from the National Cancer Institute (4) show that the estimated number 
of new AML-cases in the US for 2017 is 21 380, and the number of estimated deaths is 
10 590. The 5-year survival rate (2008-2014) was 27.4%. The median age of diagnosis is 68 
years, and patients 65 years or older accounts for 57.4% of new cases, and 70.8% of deaths. 
The oldest patients are often those who least tolerate the current treatment, as they often have 
a higher rate of comorbidity factors, such as already onset heart disease, and in general have 
poorer ability to metabolize drugs, due to for instance slower enzymatic activity (5). The 
national guidelines for AML- treatment in Norway recommends a milder course of treatment 
for patients over the age of 65 years (6). 
 
1.1.1.  Cytogenetics and cell signalling in AML 
 
AML patients represent a highly diverse group regarding cytogenetics, and there has not been 
identified one common denominator in the cytogenetics of these patients. There are two 
classification systems that subtype patients based on two different approaches (7); 
- The French-American-British (FAB) classification system, which divides into 
categories based on which type of leukocytes the AML blasts originated from, as well 
as the maturation status of the blasts. 
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- The World Health Organisation (WHO) classification system, which is a more 
complex system, categorising patients emphasising alterations in their cytogenetics.  
 
Classification based on genetic alterations makes for a better stratification of patients, as it 
makes use of the few common denominators that are found for certain patients, and some of 
these factors has shown to be significant to the prognosis for the patients. It also emphasises 
that there is not one mutation that is present in all AML patients.  
Cytogenetic alterations include alterations affecting the factors FLT-3 ITD, p53, AMPK- and 
cytokine-signalling.  
The FLT-3 gene encodes the fms-like tyrosine kinase 3, which is part of the receptor tyrosine 
kinases, and, when the receptor is activated, sends downstream signals that induce cell 
proliferation through STAT 5 and RAS/RAF/PI3 kinases. A mutation in the FLT-3 gene leads 
to constitutive activation of the receptor, and this mutation is associated with poor prognosis 
for the patient (8).  
Mutation in the tumour suppressor gene, TP53, is also associated with poor prognosis. The 
gene acts as a tumour suppressor by detecting damaged DNA and signal to downstream 
effectors if the cell should repair its DNA or undergo apoptosis. TP53 is thus central to 
prevent cells with damaged DNA to proliferate and non-functional p53 (the protein TP53 
encodes for) causes accumulation of mutations in the cells (9, 10).  
The nucleophosmin (NPM1) gene increases the response of p53 and promotes the suppression 
of proliferation of damaged cells, both by direct interaction with p53, and by inhibiting a 
ligase that causes degradation of p53 (11). Mutation in NPM1 in the absence of FLT-3-
mutation is associated with a favourable prognosis (12).  
Cytokines is a class of peptide-hormones that mediates signals between cells and contribute to 
cell growth and proliferation. It has been shown that amongst others, IL-6 and IL-10 is 
upregulated in AML-patients. Elevated level of IL-6, which is a pro-inflammatory cytokine is 
associated with poorer prognosis, and high levels of IL-10 is associated with better prognosis 
(13). 
AMP-activated protein kinase (AMPK) is a key regulator and sensor of the metabolic state in 
the cell. One of its regulators is the ATP/AMP-ratio, which will activate AMPK if the level of 
ATP decreases, a condition called metabolic stress (14). Activated AMPK will increase 
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catabolic activities like lipolysis to enhance the generation of ATP (15). As Figure 1 shows, 
the AMPK complex is centrally located in several pathways controlling the metabolism of a 
cell.  
The mechanistic (or mammalian) target of rapamycin (mTOR) complex is an important 
kinase for protein synthesis and cell survival through the phosphorylation of the S6 kinase and 
4E-binding protein 1 (4E-BP1), which when phosphorylated regulates translation of mRNA in 
protein synthesis. Protein kinase B (AKT) activates mTOR. The levels of AMPK and mTOR 
are inversely linked, as AMPK inhibits mTOR (16, 17).  
The cell signalling in cancer is complex and still far from fully understood. As the factors in 
the cell signalling system are linked together, there are a number of potential drug targets to 
be identified in a cancer cell.  
 
 
Figure 1: Schematic display of signalling pathways in a cell, focusing on AMPK-signalling. Picture 




1.2. Current AML- treatment  
 
Since AML does not cause development of solid tumours that can be surgically removed or 
radiated, chemotherapy is the most common treatment, which is often harmful to normal cells 
and tissues. The recommended treatment for AML in Norway is summarized in the National 
guidelines for diagnostics, treatment and follow-up of malignant blood diseases from the 
Norwegian Directorate of Health. The most common course of treatment is divided into two 
phases, induction therapy and consolidating therapy (18). The induction phase consists of 
high dose chemotherapy infusions; the anthracycline daunorubicin (DNR) or idarubicin 
combined with the pyrimidine nucleoside analogue cytarabine. The goal of the induction 
therapy is to eradicate all visual signs of disease, also known as complete remission (CR) 
(19). CR is defined as; <5% blasts in bone marrow sample, >1×109 granulocytes/L, >100×109 
blood plates/L, and absence of extramedullary manifestations. 
To achieve CR it is necessary to use doses of chemotherapy which is close to the maximum 
tolerable dose of the patient, and in up to 5% of the cases the patient dies of complications 
from the chemotherapy, known as therapy related mortality (TRM) (18). These complications 
include granulocytopenia and thrombocytopenia; the former will also increase the risk for 
severe infections by opportunistic bacteria and fungi. This makes it necessary with support 
therapy like blood transfusions and antibiotic/antimycotic treatment. Not all patients are 
eligible for this intensive therapy, especially patients over 65 years of age, patients with poor 
general condition, and patients with other diseases that weakens their immune system. Since 
the group of patients over 65 years account for the majority of both new cases and deaths, and 
is also the group of patients that is most difficult to treat, the need of a tolerable treatment is 
essential. 
If the patient achieves CR, the next phase of treatment is the consolidating therapy to 
eradicate any remaining AML cells in the blood and bone marrow, and to prevent relapse of 
the disease. This treatment consists of repeated cycles of chemotherapy. If there is a 
substantial risk of relapse, there is an option to perform allogenic stem cell transplantation. 
This treatment also requires pre-treatment with chemotherapy, and the TRM-rate is 15-20% in 
younger patients (18). The 3-year survival rate is ~50% for patients who are in CR when they 
receive allogenic stem cell transplantation. If the disease is still in an active state the 3-year 
survival is only 15% (20). 
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In addition to the effects the anthracyclines have on the immune system of the patients, it is 
commonly known that this class of compounds give a dose-dependent risk of both acute and 
later onset cardiomyopathy and heart failure (21). It is therefore a dire need for drugs which 
can be tolerated by AML patients with poor general condition, or with compromised immune 
system or cardiac function. 
Contrary to AML, in chronic myeloid leukaemia (CML) there is identified a common 
denominator in the cytogenetics, where most of patients, where most of them carry a mutation 
in chromosome 22, which results in a constitutively active tyrosine kinase, BCR-ABL (22). 
An inhibitor of the BCR-ABL tyrosine kinase, imatinib (Glivec ®), was developed, which led 
to an improved 5-year survival rate, which in 2008-2014 was 67.6% (23).  
Despite the lack of a general target in AML cells, there have been some recent advances in 
AML therapy, and some new drugs have been approved by the FDA lately. Midostaurin is an 
inhibitor of the FLT-3 receptor and is used in combination with standard chemotherapy. 
Although contributing to a progress in AML treatment, the FLT-3 mutation is only present in 
~30% of AML patients, and the effect of FLT-3 inhibitors have shown to be short-lasting 
(24). Vyxeos ® is a fixed (5:1 molar ratio) combination of cytarabine and DNR in a liposomal 
formulation (25). The liposomal formulation ensures that the ratio of the drugs remain fixed 
compared to injecting them into the blood separately. Gemtuzumab ozogamicin (GO) is an 
antibody-drug conjugate targeting the CD33 antigen. It is conjugated with a calicheamicin 
derivative, which induces damage to the DNA of the cell (26). Not all patients are positive for 
the CD33 antigen, and the drug is associated with hepatoxicity (27), which limits the benefit 
of the drug. Tirapazamine is a compound that induces DNA-damage through generation of 
radicals in hypoxic environment. It has shown favourable effects against cancer used in 
combination with radiation or cisplatin (28).  
In conclusion, there are several treatment options for AML, but none of them represent a 
universal drug-therapy solution, as some of them are only specific to some cytogenetic 
mutations, and most of them are associated with severe side effects, and clinical trials has 






1.3. Reactive Oxygen Species (ROS) and its relationship to cancer  
 
Reactive oxygen species (ROS) is the common name for molecules with unpaired electron, 
also known as radicals. The formation and removal of reactive oxygen species is a fine-tuned 
process in the cell. Endogenous factors, such as complex I in the mitochondrial respiratory 
chain is known to produce ROS at normal conditions, but also exogenous factors can increase 
the production, for instance when the body is exposed to UV- light, physical activity or redox-
reactions caused by xenobiotics, resulting in what is known as oxidative stress (29). The body 
utilises numerous counter measures, amongst other antioxidants to remove the reactive 
oxygen species, see section 2.8.1 and 2.8.2 for examples. 
 
The metabolic activity is altered in cancer cells relative to normal cells, as a part of their 
survival system. Cancer cells perform anaerobic glycolysis regardless of oxygen levels in the 
cell, known as the Warburg effect, and this is reported to increase the levels of ROS (30). The 
cancer cells try to counteract this by upregulation of the production of antioxidants (31).  
 
Since high levels of ROS is known to induce cell death, several cancer treatments try to 
increase the ROS-production to levels beyond the point of antioxidant counteraction, or to 
deplete the cell of the antioxidants itself (31). One example is radiation therapy, which 
induces ROS-mediated DNA damage. Such treatments should preferably cause increased 
ROS-levels selectively in cancer cells, as increased levels of ROS can also damage normal 
cells and tissues. It is important that the ROS induction is high enough to surpass the stage of 
where cancer cells can be rescued, as low levels of ROS has shown to enhance signalling 
pathways linked to metastasis and tumour growth (32). 
 
1.4. Anti-cancer drug development  
 
The low survival rate of AML patients demonstrates the urgent need for new and improved 
treatments. Therapy with monoclonal antibodies has been described as revolutionary to the 
field and is important it the treatment of severe diseases like autoimmune diseases and 
cancers. However, the U.S. Food and Drug Administration’s statistics over novel drug 
approvals for 2015-2017 show that small molecule compounds are still relevant in anti-cancer 
therapy (33). The graph shows that the main fraction of new anticancer drugs as well as other 





Figure 2: FDA`s statistics over novel drug therapies approved in 2015-2017. The majority of both 
anti-cancer and other drugs have a molecular weight below 1000 Dalton. Drugs with a molecular 
weight ~150 000 Daltons is monoclonal antibodies. 
 
There are several obstacles to overcome when it comes to drug development. To find a 
promising compound, a “hit”, it is possible to e.g. screen compound libraries or compounds 
identified from natural sources for affinity towards a known target. The hit found from the 
screening of compounds may not be suitable to use directly as a drug and needs to be 
optimized in a “hit-to-lead” process. In this process the structure of the hit might be altered to 
improve important properties as potency, affinity to targets, solubility, membrane 
permeability and stability. Many drugs have its origin in nature. A drug search based on 
natural sources can produce hit compounds where it is difficult to obtain substantial quantities 
from the natural source. It is therefore essential to be able to synthesise the natural compound. 
If the structure is too complex to be effectively synthesised it is possible to perform a 
structure-activity-relationship (SAR) study to identify which part of the structure that are 
essential for biological activity, and which parts that can be removed to simplify the structure 
and synthesis (34). 
This project focus on the stage after a promising hit compound has been identified, and a 
method for synthesis of the drug was developed (35). The optimisation of the structure has led 
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to several analogues with promising properties. At this stage, further experiments must be 
conducted to be able to choose a lead molecule suitable for future development into a drug.  
The characterisation of the analogues is important to understand or discover biological effects 
of the compound that cannot be predicted. One of the most important physiochemical 
properties of a drug is its lipophilicity (36), which will have large impact on the compounds 
ability to cross or interact with biological membranes. A drug’s ability to interact with 
biological membranes will, in part, determine if and how it affects the body. Drugs that cross 
cell membranes, are likely to distribute in all tissues of the body. Drugs that binds to cell 
membranes, but do not cross, might not reach the intracellular target. Hydrophilic drugs will 
have poor ability to reach intracellular targets. Lipophilic drugs will bind to lipoproteins in the 
blood and are more likely to be distributed to adipose and liver tissue. Lipophilicity will also 
affect the metabolism of a drug, as lipophilic drugs get reabsorbed in the renal tubule, and are 
usually subjected to hepatic clearance (37). 
 
1.5. Analogues developed from the phenazine class compound iodinin 
 
The analogues used in this project are being tested for their 
effect as an anti-leukemic drug. The parent compounds of the 
analogues are iodinin and myxin, which are phenazine class 
compounds described to have anti-cancer and antimicrobial 
effect in previous literature (35, 38-40). However, iodinin has 
very poor solubility in aqueous solutions, which makes it 
difficult administer both to cells, and in animals for toxicity 
studies. One can therefore question the validity of previous 
experiments where iodinin was administered by intraperitoneal 
(i.p.) injection (41). Collaborators at the University of Oslo (UiO) 
have developed a method to synthesise iodinin (IM 5) and myxin, as well as analogues of 
these, and have produced several analogues with structural similarities to iodinin and myxin 
with improved aqueous solubility compared to the parent compounds (35, 42). Since iodinin 
is prepared by a new synthesis method, it will be named from the compound library 
identificatory (IM 5) in this master thesis. The UiO research group has synthesised close to 
one hundred analogues which have been tested for biological activity at the Herfindal research 
group at the University of Bergen (UiB). This master thesis focuses on a selected group of 
Figure 3. Structures of iodinin 
(IM 5) and myxin (IM 7). 
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analogues that show to be particularly promising as lead candidates based on their efficacy 
towards AML cells. A screening assay for permeability was performed on 42 of the analogues 
(see section 4.1.1), the rest of the work has been focused on the analogues denoted IM 5 (the 
parent compound, iodinin), IM 20, IM 56 and IM 69. See Supporting Table 1 and 2 for 




The four selected analogues have the phenazine 5,10 dioxide unit as basis for the structure, 
but with different R1 and R2 substituents (Figure 3 and 4). Both R-substituents for IM 5 are 
hydroxy-groups, which is the basis for the alterations done in the analogues. The R1 
substituent of IM 20 is the same as for IM5, but the R2 substituent is an ester group. The R2 
substituent of IM 56 is a methyl group, and the R2 substituent is a 4-methyl piperazine 
carboxylate. The structure of IM 69 differs the most from the rest, the R1 is the same as for IM 
56, but the R2 substituent at the C6 phenazine carbon is removed completely, and the C7 and 
C8 carbon is methylated.  
  
Figure 4. Structures of the 
analogues focused on in this 
project. IM 5 is the parent 
compound, iodinin.  
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1.6. Aims of this master thesis 
 
The main aim of this master is to gather sufficient information on a selection of possible lead 
compounds to be able to choose one compound for further pre-clinical studies. To achieve 
this, I will investigate the biological activity and physiochemical properties of analogues 
synthesised from a parent compound. 
The work can be divided into three parts. 
The first part will include testing the cytotoxicity of the 3 most active analogues in OCI-
AML3 cells and compare the activity to the parent compound iodinin and the anthracycline 
daunorubicin (DNR). Previous results had already been obtained concerning the cytotoxic 
effect of iodinin, myxin and analogues of these on the human AML cell line MOLM-13, and 
on the normal rat kidney epithelial (NRK) and cardiomyoblast (H9c2) cell lines. 
The second part will include examining the physiochemical properties of the analogues in 
order to find if this can explain the differences in bioactivity, and to possibly be able to 
predict their interaction with biological membranes and their pharmacokinetic properties. 
Emphasis will be put on the ability to interact with membranes. 
The third part will include studying the molecular mechanism of action of chosen analogues 




2. Experimental theory 
 
2.1. Membrane permeability 
 
Membrane permeability is an important feature to consider when developing a drug. For 
example, if the drug target is a receptor inside the cell, the effect of drug is dependent on 
whether it is able to cross the membrane of the cell. This mainly happens through passive 
diffusion or active transport across the cell membrane (43). For instance, the anthracycline 
daunorubicin (DNR) is proven to be a substrate for active transport over the cell membrane 
(44). If the cell has a defect in this transporter system, DNR will not be able to intercalate 
with the DNA inside the cell.  
 
To investigate the membrane permeability of the analogues, a Parallel Artificial Membrane 
Permeability Assay (PAMPA) was utilised.  
 




The plate system is a commercially available ready-to-use assay. It consists of one 96-well 
acceptor plate with a polyvinylidene fluoride (PVDF) membrane pre-coated with 
phospholipids as a filter in the bottom of the wells, and one 96-well donor plate, as showed in 
Figure 5 (45). Buffer without compounds is added to the acceptor plate, and the compounds of 
interest is diluted in the same buffer and added to the donor wells. Upon assembly of the plate 
system, the membrane is in contact with the liquid in both wells, and substances able to 
diffuse over the membrane will cross over to the acceptor well. The drug content in donor and 
acceptor wells is quantified by for instance HPLC-analysis and the ratio of the concentration 
of the drugs in the donor and acceptor well can be calculated as described in section 3.1. This 
calculation gives the value of the effective permeability, log Peff. 
20 
 
Bennion et al. defines the permeability from the PAMPA-assay as log Peff < -6.14 as 
impermeable compounds, log Peff > -6.14 < -5.66 as low permeability compounds, log Peff > -
5.66 < -5.33 as medium permeability compounds, and log Peff > -5.33 as high permeability 
compounds (46). 
Although valuable information of membrane permeability is obtained by this assay, it is 
important to remember that it only demonstrates the gradient-driven passive diffusion over a 
phospholipid membrane. It will not give information about how much substance is associated 
with the membrane, or if it will utilise any of the active transport systems in a cell, such as 
transport through an ATP-driven pump in the cell membrane.  
The measured permeability found by using the PAMPA-assay, Peff, was compared to clogP 
and tPSA values to investigate any correlation between measured permeability and important 




High-pressure liquid chromatography (HPLC) is a technique used to separate, identify, and 
quantify different analytes in a sample. In most cases, analytes are separated based on their 
hydrophobicity, but other physiochemical properties like charge, pH, ion strength, or size can 
also be used. A typical HPLC-system consists of a pump that degasses the mobile phase and 
maintains the desired composition and flow of mobile phase; an injector or automatic sampler 
which introduces the sample into the mobile phase; a column which separates the sample 
content; a detector (typically UV-detector) which creates a signal based on the analytes 
eluting from the column; and a computer with appropriate software to analyse the signal from 
the detector. Quantitation is done by peak integration, and based on this the amount of analyte 
can be calculated by comparing the values from the sample to the values from a standard 
curve with known concentrations (47). 
When a sample is injected into the column, the different analytes will associate to the column 
material (stationary or solid phase) with different affinity. The difference in affinity is 
amongst other due to adsorption, ion exchange and partition between the components and 
solid phase (48). Here, a reverse phase column was used, which means that the stationary 
phase is nonpolar, and the mobile phase, which here are acetonitrile and MilliQ H2O, is polar. 
21 
 
As the gradient changes from aqueous to organic solvent, the analytes will dissociate (elute) 
from the column at separate time-points during the elution.  
The HPLC-technique is a relatively quick and easy method, but it has some limitations. Since 
the affinity for the column is due to properties as adsorption and partition, it can be difficult to 
separate two analytes if they have similar polarity. Analytes that elute at approximately the 
same time and give overlapping peaks without baseline separation in the chromatogram and 
are difficult to quantify.  
  
2.3. Liposomes as a tool to study drug-membrane interactions 
 
Liposomes are small vesicles enclosed by a lipid membrane (49, p.14). Depending on the 
method of preparation, liposomes will form structures that can be divided into categories with 
approximate sizes (49, p.23): 
a) Multilamellar vesicles (MLVs) 
Consist of several membrane layers (lamellae), diameter usually between 100-1000 
nm 
b) Large unilamellar vesicles (LUVs)  
Consist of one phospholipid bilayer, with a diameter between 100-1000 nm  
c) Small unilamellar vesicles (SUVs) 
Consist of one phospholipid bilayer, with a diameter between 25-100 nm 
 
Here, SUVs were made by extrusion, where a uniform size distribution is obtained by 
extrusion through membranes (50), which yields liposomes with a size slightly smaller than 
the membrane pore size (49, p.53-54). The liposomes have the aqueous media on both sides 
of the lipid bilayer, and a compound present on the outside of the liposomes can either be 
repelled by the membrane, diffuse through the membrane, or associate with the membrane. 
After rinsing, for example by gel filtration, only the associated or incapsulated analogue 
remains in the liposome sample and can therefore give information about to what degree the 
analogue will cross or interact with a phospholipid bilayer membrane.  
Three analogues were chosen to use in the liposome- model; IM 5, IM 20 and IM 23. IM 5 
was chosen since this is the parent compound (Iodinin), IM 20 was chosen since it had shown 
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high potency in previous cell-assays. IM 23 was chosen since it had shown poor effect in 
previous cell-assays (EC50 = 50 ± 0.4 µM in MOLM-13 cells), despite being almost identical 
to IM 20 regarding structure, and could therefore be used as a negative control.  
 
2.4. Size exclusion chromatography  
 
Size exclusion chromatography, also called gel filtration, is a method that separates molecules 
or particles according to their size. A column is packed with sepharose gel beads. These beads 
are porous, and molecules small enough to enter the pores will be retained, whereas larger 
molecules will pass through the column without interfering with the beads (51). The sample is 
placed on top of the column and a running buffer elute the molecules trough the gel. The 
largest molecules will elute first, and if the molecules are of uniform size they will form a 
band in the column and elute in the same fraction.  
 
2.5. Infrared spectroscopy 
 
In order to determine lipid content in the liposome suspensions, infrared spectroscopy (Direct 
Detect ® spectrometer (DDS)) was used, which utilises infrared light absorbance at 
frequencies specific to the molecule structure. Mid-infrared (MIR) spectroscopy operates in 
the range of 4000-400 cm-1 (2.5-25µm), and can be used to analyse samples as proteins, lipids 
and carbohydrates (52). For lipids, the DDS detects the absorption of infrared light in the 
range between 2870 and 2840 cm-1, made by vibration of the C-H symmetric stretch in lipids 
(53).  
A lipid sample is analysed by applying a 2 µL drop on the sample area of a Direct Detect ® 
assay-free sample card. The sample area is a hydrophilic polytetrafluoroethylene membrane 
which is transparent in the MIR region. The machine dries the sample and applies infrared 
light, and measures how much of the light that gets absorbed, and calculates the lipid 
concentration using the Beer-Lambert-law;  
𝐴 =  ε × l × C    Equation 1 
were A is absorbance, ε is the molar absorptivity, l is the path length of the sample, and C is 
the concentration in the sample (52). 
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2.6. Cell lines  
 
The MOLM -13 cell line (ACC-554), is a human AML cell line which carries an internal 
tandem duplication of FLT-3 (FLT-3 ITD) (54, 55). The OCI-AML-3 cell line (ACC-582) 
(56) is a human AML cell line without the internal tandem duplication of FLT-3. Both cell 
lines are suspension cells.  
Since current treatment with anthracyclines is known to cause damage to the heart, the normal 
H9c2 rat cardiac myoblastic cell line (ATCC no: CRL-1446), was included in the study.  
H9c2 is an adherent cell line, and if this cell line grows to confluency the myoblastic 
population will be depleted, so the cell line needs to be sub-cultured before it gets confluent 
(57). 
Cultured cell lines represent an important model to study the effect of a desired treatment, and 
it can give important indications of e.g. effect and toxicity. Although important information is 
obtained by assays performed on cell lines, it is important to remember that the results can not 
directly be compared to an in vivo study, as a cell line is highly homogenous, and does not 
represent the complexity of the total system in the body. Therefore, in vitro studies on cell 
lines give the basic information needed to advance into in vivo studies in e.g. mice and 
eventually in humans.  
 
2.7. Cell viability and EC50-values 
 
To find the effective concentration (EC50) for treatments with cytotoxic compounds, which 
here means the concentration needed to induce 50% cell death, a WST-1 cell viability assay 
was performed. The EC50 values for MOLM-13, H9c2, and NRK- cells (a kidney epithelial 
cell line from rat) has previously been determined by WST-1 and is here compared to the 
results from doing the same assay on OCI-AML-3 cells.  
 
The WST-1 assay utilises the ability a metabolic active cell has to convert a tetrazolium salt, 
WST-1, into the reduced formazan product. This product has a distinct colour that can be 
detected by a spectrophotometer, measuring absorbance at 450 nm, with a reference read at 
620 nm (58, 59). The tetrazolium salt is believed to be cleaved in a reduction process which is 
dependent on NADPH, which is formed in viable cells. This means that the more 
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metabolically active cells is present in the well, the more formazan is produced, and thus the 
colour intensity will correlate to the number of viable cells.  
 
To confirm the results from the WST-1 assay a manual count of apoptotic/dead cells was 
performed. The cells were fixed in a 2 % buffered formaldehyde solution and the nuclei were 
visualised by adding the DNA-specific blue fluorescent dye Hoechst 33342 in the fixative 
(fix-solution). The dye enters the cell and binds to the adenosine-thymine rich regions of the 
minor groove in the DNA (60). If the cell is dead or apoptotic, its nucleus will be condensed 
and visible as a bright spot in the cell. In live cells the DNA is less condensed, and the nuclei 
appear less bright (61) . If the cells have undergone rapid and uncontrolled cell death, the 
apoptotic processes might not be complete, and these cells can be difficult to distinguish from 
normal cell nuclei. This can occur if the cells have been treated with high concentrations of a 
cytotoxic analogue (62).  
 
 
2.8. Selected cell-active compounds used in combination with phenazine analogues  
 
2.8.1. Sulfasalazine (SAS) 
 
Sulfasalazine, ((E)-2-hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic 
acid), is sulpha class compound, used as an anti-inflammatory drug against rheumatoid 
arthritis and other autoimmune diseases. It is registered in Norway under the brand name 
Salazopyrin EN (Pfizer) (63).  
Sulfasalazine acts as an inhibitor of the xc
- cystine/glutamate antiporter. Cystine is taken up 
into the cell and reduced to cysteine, which is a precursor for glutathione (GSH) (64). 
Glutathione acts as an antioxidant and reduces reactive oxygen species by being catalysed by 
the enzyme glutathione peroxidase (65). If the glutathione store in the cell is depleted by the 
inhibition of cystine uptake, the cell loses an important protective mechanism against ROS-
induced damage and is therefore more likely to undergo apoptosis.  
 




N- acetyl cysteine (NAC) is a thiol containing compound, which is used as a mucolytic drug, 
and is registered in Norway under several brand names, e.g. Bronkyl (Weifa) (66).  
 
NAC is considered to be a direct scavenger of reactive oxygen species but is also a precursor 
of glutathione (67, 68), which means that NAC has the ability to reduce the levels of ROS in 
the cell. Thus, NAC acts as a protectant from ROS-induced cell death.  
 
2.8.3. Phenformin (PhF) 
 
Phenformin, (3-(diaminomethylidene)-1-ethyl-1-(2-phenylethyl)guanidine), is a compound of 
the drug class biguanides, which is used to treat metabolic diseases, such as diabetes. It is 
more potent than its related compound metformin, and associated with more severe side 
effects, and thus not used as an antidiabetic drug today (69). Metformin is therefore better 
studied, and has shown promising effects as an anti-cancer agent (70). The possible use of 
metformin in cancer therapy has also renewed the interest for phenformin.  
Metformin is an inhibitor of complex I in the mitochondrial respiratory chain (71) and this is 
also shown to be true for phenformin (31, 72). The inhibition of complex I 
(NADH:ubiquinone oxidoreductase) prevents the coenzyme NADH from transferring 
electrons to complex I, and the lost energy prevents H+ from being excreted, and thus there is 
no influx of H+, which drives the energy-dependent catalysis of ADP to ATP by the enzyme 
ATP-synthase (73, 74). Less ATP- production leads to an increase in the AMP/ATP- ratio, 
which in turn activate the AMP-activated protein kinase (AMPK) (75). 
Since phenformin is a known activator of AMPK, it can be used as a positive control to study 
AMPK-phosphorylation by for instance western blotting, where it gives increased 





2.9. ROS detecting assay 
 
There are several fluorescent probes which can be used to measure the intracellular levels of 
reactive oxygen species (ROS) (76). In the present study we used 2’,7’-dichlorofluorescin 
diacetate (DCF-DA), which is non-fluorescent in its reduced state, and permeates the cell 
easily. Here, cellular esterases deacetylates DCF-DA, and this deacetylated substance is 
oxidised by ROS to 2’,7’-dichlorofluorescin (DCF). DCF emits green fluorescence, with a 
maximum excitation spectrum at 495 nm, and maximum emission spectrum at 529 nm (77). 
DCF-DA can be used in assays to measure ROS in both adherent and suspension cells.  
 
There are some issues to consider when using the DCF-DA-assay; it cannot differentiate 
between the various ROS species like superoxide (*O2-), hydroxyl radical (*OH) or hydrogen 
peroxide (H2O2), and it is not photostable (76, 78). The lack of specificity is usually not a 
problem if you want to measure the total amount of ROS. The low photostability influence 
how you should set up your assay to keep the access to light to a minimum. It is therefore 
important to have a satisfying control sample setup, so that it is possible to remove the 
background signal from both medium, untreated cells, and cells treated only with DCF-DA. If 




2.10. Western blotting 
 
Western blotting is a widely used method to identify specific proteins from a mixture of the 
total protein content in a sample. The method includes several steps; preparing a cell lysate 
sample, separating the proteins by electrophoresis, transferring the protein bands to a 
membrane, and visualisation of the protein bands by antibodies (79).  
The preparation of cell lysate is done by subjecting the cells to the desired treatment, which 
here meant incubating cells with the analogues, rinsing the cells for excess drugs, lysing the 
cells to get all proteins in a mixture, and rinse the lysate from other cell components by 
centrifugation.  
Proteins are separated using gel electrophoresis, where the mixed proteins get separated by 
applying an electrical force which makes the negatively charged proteins migrate through a 
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polyacrylamide gel (80). Smaller proteins will migrate faster than larger proteins and the 
proteins from the total sample are separated by their size.  
The proteins from the gel is transferred (blotted) to a polyvinylidene fluorene membrane and 
the membrane is blocked to prevent unspecific binding of the antibodies. The membrane is 
incubated with primary antibodies that are specific to the protein of interest, and then re-
incubated with a secondary antibody, which is specific to the species that is the source of the 
primary antibody (e.g. mouse or rabbit). The secondary antibody is often conjugated with an 
enzyme, which, when in contact with an appropriate substrate, will produce a detectable 
signal. To control that equal amounts of protein is loaded into each well of the electrophoresis 
gel, a loading control is used. Antibodies against β-actin are commonly used, as β-actin is a 
“housekeeping” protein, which is a group of proteins equally expressed in cells. This will 
usually give an even band for each well, provided correct loading.  
Although being a widely used method, there are also some drawbacks with the method (81). It 
is relatively time-consuming, as the incubation for each antibody is done overnight and each 
step (blotting, removing of both antibodies and stripping) requires a washing cycle, here 2×5 
minutes + 15 minutes. It is also possible to get non-specific binding to proteins, or weak 
detection if the antibody is degraded. Correct handling of the protein samples is also 
important to prevent degrading of the proteins, for example by heat or proteasomes. Finally, it 





3. Material and methods  
 
3.1. Parallel Artificial Membrane Permeability Assay (PAMPA) 
 
The assay used to determine to which extent the analogues could cross membranes was the 
Corning ® Gentest ™ Pre-coated PAMPA Plate System from Corning Discovery Labware 
Inc (Bedford, USA). The analogue stock solutions were diluted in phosphate buffered saline 
(PBS) to 50 µM, and 300 µL was added to each well in the donor plate. 200 µL PBS was 
added to the receiver plate, the plate system assembled, and incubated for 5 hours in the dark 
at room temperature (21°C). After incubation, the content of each well was quantified by 
HPLC-analysis, and the ratio of the concentration of the analogues in the donor and acceptor 
well was calculated.  
The effective permeability (cm/s) was calculated using Equation 2 (82): 
 
𝑃𝑒𝑓𝑓 =
−ln [1−𝐶𝐴 (𝑡)/𝐶𝑒𝑞 ]
𝐴×(1/𝑉𝐷 +1/𝑉𝐴 )×𝑡
      Equation 2 
  
where A is the area of the filter plate membrane (0.3 cm2), VD is the volume in the donor well 
(0.3 mL), VA is the volume in the acceptor well (0.2 mL), CA(t) is the concentration in the 
acceptor well at time t, and t is the time of incubation (18 000 s). Ceq was calculated using 





      Equation 3  
   







The HPLC system was a Merck-Hitachi LaChrome (VWR, Westchester, USA) which 
consisted of Merck L-7614 pump (Merck KGaA, Darmstadt, Germany), a manual injector 
(Rheodyne ® model 7725i), a Kromasil 100-5 C18 150-4.6 mm column, a L-7455 diode array 
detector, Hitachi Interface D-7000 (Hitachi Instruments Inc., San Jose, Ca, USA), and the data 
processing software D-7000 HPLC System Manager (HSM), version 4.1 (Merck KGaA, 
Darmstadt, Germany/Hitachi Instruments Inc., San Jose, Ca, USA). 
The pump was coupled to a reversed phase column (Kromasil 100-5 C18 150-4.6 mm, Akzo 
Nobel, Sweden), fitted with a 10 x 4.6 mm C18 guard column (Akzo Nobel, Sweden). Mobil 
phase A was MilliQ H2O added 0.05% trifluoroacetic acid (TFA), and mobile phase B was 
acetonitrile (ACN). The gradients used is shown in Table 1 and 2. Peak integration was 
calculated at 285 nm. The samples were injected into the column using a 250 µL syringe 
(Gastight ® #1725 from Hamilton Bonaduz A.G., Bonaduz, Switzerland) in a manual injector 
















phase B  
(Acetonitrile)  
[%] 
0.0 70 30 
0.5 70 30 
4.0 0 100 
4.5 0 100 
5.5 70 30 
8.0 70 30 
 














0.0 90 30 
0.5 90 30 
4.0 0 100 
4.5 0 100 
5.5 90 10 
9.0 90 10 
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3.3. Preparation of liposomes 
 
Liposome solution was prepared by dissolving 24 mg 95% Lecithin (Soy) L-a-
Phosphatidylcholine (Soy-95%) (Avanti Polar Lipids, Inc., Alabaster, AL, US) in chloroform 
(Sigma-Aldrich, St. Louis, USA). 5 mL of this solution was allowed to dry on a Laborota 
4000 rotavapor, (Heidolph instruments, Germany), at room tempered water bath at 150 rpm, 
and pressure of 175 mbar for 45 minutes, to create a thin lipid film, followed by 2 hours at 
maximum vacuum pump capacity (6-7 mbar) to remove residual chloroform. The lipid film 
was hydrated to create LMV by adding 5 mL PBS (pH 7.4) from Sigma-Aldrich (St. Louis, 
USA), and shaking it on a Vortex-Genie 2, (Scientific industries Inc., New York, USA), and 
then on the rotavapor without vacuum for additional 25 minutes. 
 
Small unilamellar liposomes were prepared from the liposome solution using a Mini Extruder 
from Avanti Polar Lipids, Inc. (Alabaster, AL, US). The liposome solution was extruded 
eleven times through Whatman ® Nucleopore Track-Etched membrane filters with pore size 
0.4 µm, 0.2µm and 0.1 µm to obtain the desired size. 
Total lipid concentration in the liposome suspension was determined using a Direct Detect ® 
spectrometer (DDS) from Merck KGaA (Darmstadt, Germany). A previously obtained 
standard curve (83, p.36), which gave Equation 4, was used to calculate the total lipid 
concentration by interpolation of a linear regression curve. 
 
Standard curve: 𝑦 = 0.0147𝑥    Equation 4 
 
3.4. Compound association to liposomes 
 
The analogues were added to 500 µL of liposomes, at a molar ratio corresponding to 1% of 
total lipid concentration. The liposomes were incubated with the analogue at room 
temperature for 1 hour before gel filtration through a column (200 × 10 mm), (Bio-Rad, 
Hercules, USA), packed with Sephadex™ G50 medium from GE Health Bio-Science AB 
(Uppsala, Sweden) (51), using degassed PBS (pH 7.4) as running buffer. Fractions of 0.4 mL 
were collected using a fraction collector (Bio-Rad Model 2110, Hercules, USA). 
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Sample fractions were dried in a vacuum centrifuge Concentrator Plus, Eppendorf (Hamburg, 
Germany), and added 150 µL of acetonitrile:milliQ H2O (30:70) to prepare the samples for 
HPLC- analysis. The acetonitrile was HPLC-grade from Merck KGaA (Darmstadt, Germany).  
The liposome-samples were analysed using HPLC (see section 3.2), and the result was 
compared to the result from HPLC- analysis of a standard curve prepared for each analogue to 
determine the amount of analogue associated with the liposome.  
 
3.5. Cell lines  
 
The MOLM -13 and OCL-AML-3 cell lines were cultured in RPMI 1640 medium (R5886), 
with 50 IU/mL penicillin, 0.1 mg/mL streptomycin (P0781), 0.2 mM L-Glutamine (G7513) 
and 10% foetal bovine serum (FBS) added. The incubation condition was 37°C in the dark 
and 5% CO2 in air.  
The H9c2 was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented 
with 10% FBS and 0.1 mg/mL streptomycin (P0781), and incubated at the same conditions as 
the MOLM-13 cells. Sub-culturing the cells was done at 90% confluency. The cells were 
detached from the incubation flask, by washing twice with room tempered PBS and 
incubating with 0.33 mg/mL trypsin for 2-3 minutes at 37°C. The cells were next centrifuged 
at 200×G for 3 minutes and the cell pellet reseeded in fresh medium with supplements and the 
cells were reseeded in new culture flasks at 40-50% confluence.  
All medium and supplements obtained from Sigma-Aldrich (St. Louis, MO, USA). 
 
3.6. Assessment of cell viability by metabolic activity and nuclear morphology 
 
Cell viability was assessed using WST-1 viability assay to find EC50- values for analogue 
treatment of OCI-AML-3 cells. These results are compared to results from other cell lines in 
Table 5, where the experiments have been performed by my supervisor Reidun Æsøy. The 
WST-1 assay was also used to study the viability of MOLM-13 cells treated with 
sulfasalazine (SAS) and phenformin.  
Cells were incubated for 22 hours with increasing doses of analogues, daunorubicin (DNR), 
cell active compounds or solvent in a clear 96-well plate at a concentration of 10-20 000 
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cells/well and added 10 µL WST-1 
solution, which was allowed to incubate 
with the cells for 2 hours before 
measuring absorbance at 450 nm, with a 
reference read at 620 nm using an Infinite 
® M200 Pro plate reader using 
Magellan™ software (Tecan Trading AG, 
Zürich, Switzerland).  
Results from the WST-1 assays were 
confirmed by microscopic evaluation of 
cells fixed in 2% buffered formaldehyde 
(pH 7.4) containing the fluorescent DNA 
dye Hoechst 33342 (0.01 mg/mL) and 
counting approximately 200 living and apoptotic/dead cells per well (Figure 6). The 
percentage of apoptosis for treated cells were adjusted relative to untreated control cells by 
applying Equation 5. Ds = Percent apoptosis in sample, Dc = percent apoptosis in control 
cells.  
Apoptosis relative to control cells = 𝐷𝑠 − (𝐷𝑐 ×  
100−𝐷𝑠
100−𝐷𝑐
)  Equation 5 
 
 
3.7. Detection of reactive oxygen species in cells 
 
 
3.7.1. Protocol for measuring ROS in H9c2 adherent cells 
 
One day prior to the experiment 6000 cells were seeded per well into black 96-well plates 
with clear bottom and incubated at 37°C and 19% O2.  
 
At the day of the experiment the medium was removed from the wells, and the cells washed 
twice with serum-free medium. Half of the wells were incubated with 20 µM DCF-DA in 
serum-free DMEM for 30 minutes in the dark, the other half with serum-free medium only. 
Figure 6. Fixed cells were counted manually by microscopy 
to assess cell viability based on nuclear morphology. 




The cells were next washed three times with PBS (37°C), and 100 µL DMEM with 10% FBS 
containing analogues, H2O2 (positive control) or solvent was added to its respective wells and 
placed in the incubator. ROS generation was recorded by measuring the fluorescence at 
wavelengths 485 nm (excitation) and 535 nm (emission), using a Synergy H1 hybrid 
spectrofluorometer with the Gen5 software (version 2.00.18) from BioTek Instruments, Inc. 
(Bad Friedrichshall, Germany) at selected time-points. 
 
3.7.2. Protocol for measuring ROS in MOLM-13 suspension cells 
 
Two cell conditions were prepared in a 50 mL centrifuge tube; 5×106 cells were transferred to 
each tube, centrifuged at 200×g for 3 minutes, the supernatant decanted off, and the cells were 
washed once with serum-free RPMI. One tube was incubated with 20 µM DCF-DA in serum-
free RPMI for 30 minutes in the dark, and one was incubated in serum-free RPMI only. The 
cells were washed three times in serum-free medium and resuspended in 5 mL RPMI with 
10% FBS and supplements. 50 000 cells were seeded in 50 µL medium in each well of a 96 
well plate, and added 50 µL medium containing FBS and supplements, as well as analogues, 
H2O2, or solvent to its respective wells. The cells were incubated in the dark at 37°C. ROS 
generation was recorded by measuring the fluorescence at wavelengths 485 nm (excitation) 
and 535 nm (emission) using a Synergy H1 hybrid spectrofluorometer with the Gen5 software 





3.8. Western Blotting 
 
After treatment with selected analogues or compounds, MOLM-13 cells were washed twice in 
isotonic saline solution by centrifugation at 1200 rpm for 5 minutes at 4°C. The cells where 
then lysed in 100 µL SHIE-buffer containing 10 mM Tris HCl (pH 7.5), 1 mM EDTA, 400 
mM NaCl, 10% glycerol, 0.5% NP-40, 5 mM NaF, 0.5 mM sodium orthovanadate, 1 mM 
DTT, added cOmplete™ Mini Protease Inhibitor Cocktail from Sigma-Aldrich, Inc. 
(Darmstadt, Germany). The lysis was done by incubation on ice for 30 minutes before 
centrifugation at 13 000 rpm for 30 minutes at 4°C.  
Protein concentrations were determined using the Quick Start Bradford protein assay (#500-
0205) from Bio-Rad Laboratories (Hercules, USA), according to manufacturer’s instructions 
(84, 85), using bovine serum albumin (BSA) as standard. 30 µg protein was mixed with 
loading buffer containing 1% SDS, 10% Glycerol, 12 mM Tris-HCl pH 6.8, 50 mM DTT and 
0.1% Bromophenol Blue. The samples were heated to 100°C for 10 minutes, and then loaded 
on a ten percent SDS-polyacrylamide gel. The pre-labelled standard, Precision Plus Protein 
Standard All Blue (#1610373) from Bio-Rad Laboratories (Hercules, USA) was used as a 
protein ladder. The gel was run at 100 V for 90 minutes before proteins were transferred to 
polyvinylidene fluoride (PVDF) membranes, from GE Healthcare Life Sciences, 
(Buckinghamshire, UK) by electrophoresis by running the blots at 100 V for 70 minutes. 
After blotting, the membranes were blocked in 5% BSA in TBS-T for 1 hour with gentle 
shaking, before overnight incubation at 4°C with the primary antibody. The next day the 
primary antibody was removed, the membranes washed in TBS-T, and incubated with the 
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15-20 kDa 1:1000 Rabbit Cell Signaling 
Technology, Inc 
(Danvers, USA) 
Anti β-actin 42 kDA 1:10 000 Mouse Sigma-Aldrich, 
Inc (Darmstadt, 
Germany) 
Phospho-p70 S6 Kinase 
(Ser371) Antibody 
#9208 
70-85 1:1000 Rabbit Cell Signaling 
Technology, Inc 
(Danvers, USA) 
p70 S6 Kinase 
Antibody #9202 
70-85 1:1000 Rabbit Cell Signaling 
Technology, Inc 
(Danvers, USA) 
Akt1 Antibody (B-1): 
sc-5298 
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Membranes were developed using SuperSignal® West Pico or West Femto Maximum 
Sensitivity Chemiluminescence Substrate from Thermo Fisher Scientific Inc. (Waltham, MA, 
USA) according to the manufacturers' protocols. The membranes were imaged by a LAS-
4000 image reader from Fujifilm (Tokyo, Japan) using the ImageQuant Las4000 control 
software (version 1.2). After imaging the membranes were stripped using Restore™ PLUS 
Western Blot Stripping Buffer #46430, from Thermo Scientific Inc (Waltham, MA, USA) 
before re-incubation of the membranes with the antibody for the total version of the proteins. 
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Anti β-actin was used as loading control. As a control for apoptosis, before lysis, 100 µL cell 
solution from each treatment condition were transferred to a 96-well plate with 2% buffered 
formaldehyde (pH 7.4) containing the fluorescent DNA dye Hoechst 33342 (0.01 mg/mL), 
and percentage of apoptosis was determined as previously described. Protein amounts was 
quantified from western blot pictures using the Analyze>Gel tool in ImageJ® software, 
version 1.51j8 (Wayne Rasband, National Institutes of Health, USA). An example of the 
quantification histogram of AMPK is shown in Supporting Figure 3. 
 
3.9. In silico modelling of phenazine analogues 
 
The clogP and tPSA values were determined by drawing the structures in ChemDraw 
Professional, ver. 16.0.1.4 (77) (PerkinElmer Informatics, Inc. Waltham, MA, USA), and 
using the “Chemical properties” window.  
 
3.10. Statistical analyses  
 
Data are presented as average and standard deviation (n≥ 3). For n = 2 the data are presented 
as average and the two measurements. The data was processed using Windows ® Excel ® 
2016 MSO for Windows, ver. 16.0.8431.2046, (Microsoft corp. Washington, USA). 
The Pearson correlation coefficient was determined using Windows ® Excel ® 2016 MSO for 
Windows, ver. 16.0.8431.2046, (Microsoft corp. Washington, USA). The coefficient is a 
number between -1 and 1 and indicates if two sets of data are related linearly. If the 
coefficient is -1 or 1 it indicates a perfect match, if it is 0 there is no linear relation between 
the data sets (86).  
Analysis of variance (ANOVA) and least significant difference (LSD) post hoc tests were 
used to find differences in ROS generation in treated and un-treated cells. To find between-
subject effects of NAC and analogues on ROS generation, a univariate analysis of variance 
was performed using the general linear model tool in IBM SPSS statistics for Apple, ver. 24, 






4.1. Selection of drug candidates based on in physiochemical properties and 
cytotoxicity towards AML cell lines 
 
4.1.1. The substituents determine membrane permeability of the phenazine analogues 
 
As the different substituents are introduced, the new compounds will have altered chemical 
properties compared to the parent compound. This will again influence how the compounds 
behave in in vitro cell experiments, and eventually also in the blood. One chemical property 
that determines both cytotoxicity and biodistribution of drugs is the ability to diffuse through 
membranes. To assess to which extent the phenazine-analogues could passively cross 
membranes, the parallel artificial membrane permeability assay (PAMPA) was used. The 
effective permeability Peff, was calculated by applying Eq. 2 and 3 in section 3.1 on the ratio 
between the donor and acceptor well. The calculation for each analogue gave the results 
presented in Figure 7. The analysis of 42 analogues show that 32 analogues can be classified 
as having high membrane permeability, two had intermediate permeability, three had low 
permeability, and five analogues were impermeable. The parent compounds iodinin and 
myxine (IM 5 and IM 7 respectively) were classified as low (IM 5) and high (IM 7) 
permeability compounds. For comparison, the N-oxide containing compound tirapazamine 
(TPZ) and the AML drug daunorubicin (DNR) was also tested. TPZ had low membrane 
permeability, whereas DNR was found to be impermeable. IM 56 was classified as a low 









Figure 7. The diverse analogues show differences in permeability. The effective permeability Peff, was calculated 
using results from the HPLC-analysis and applying them in Equation 2 and 3, as described in section 3.1 and 
3.2. The PAMPA assay defines drug permeability as high when log Peff > -5.33, intermediate as log Peff > -5.66 < 
-5.33, low as log Peff > -6.14 < -5.66 and impermeable if log Peff < -6.14. n=2 for IM 21, IM 24, IM 30, IM 33, 
IM 35, IM 36, IM 37, IM 38, IM 41, IM 42, IM 54, IM 57, IM 58, IM 60, IM 61, IM 62, IM 66, IM 68, IM 75, IM 
76, IM 84, IM 86, IM 87, tirapazamine (TPZ) and daunorubicin (DNR). n= 3-9 for IM 2, IM 5, IM 7, IM 11, IM 
15, IM 18, IM20, IM 22, IM 23, IM 27, IM 32, IM 40, IM 55, IM 56, IM 69, IM 80, IM 83, IM 88 and IM 89. 
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During the HPLC-analysis of the PAMPA samples most analogues eluted as a single, distinct  
peak as shown for IM 20 (Figure 8). Also, in most cases, the peak of the donor well was larger 
than that of the acceptor well, as shown by the multi-display of the chromatograms for donor 
and acceptor well (Figure 8), which indicates that the concentration of the compound is higher 
in the donor well than the acceptor well. The higher the difference, the less compound has been 




Figure 8. Multi-display of the HPLC-chromatograms obtained at wavelength 285 nm for donor 
(yellow) and acceptor (red) well of IM 20. The analogue eluted as a distinct peak with a retention time 
of 3.95 minutes for both donor and acceptor, but smaller amounts of the analogue is present in the 





In some cases, it was noticed that the analogue eluted in more than one peak, for instance the 
analogue IM 23. Structure for IM 23 is shown in Supporting Table 1. As presented by the 
multi-display of the chromatograms of the donor and acceptor well in Figure 9, the donor well 
(yellow line) showed several peaks with a retention time between 3.9 and 7 minutes, and it 
was not possible to separate the peaks. This was in contrast to the chromatogram obtained 
from the stock solution, which showed one distinct peak similar to IM 20 (not shown). The 
chromatogram from acceptor well for IM 23 (Figure 9, red line) shows that small amounts of 
the analogue cross the phospholipid membrane. The ratio for AUC for all peaks in the donor 
well compared to the acceptor well was 940:1.  
 
 
Figure 9. Multi-display of the HPLC-chromatograms obtained at wavelength 285 nm for donor 
(yellow) and acceptor (red) well of IM 23. The analogue eluted as several peaks with a retention time 
of approximately 3.90-7.00 minutes for the analysis of the donor well. Little of the analogue crosses 
the phospholipid membrane, the peak identified as an analogue is marked by arrow. The peak at 




4.1.2. Association of analogues to liposomal membranes 
 
Although the analogues’ ability to cross membranes is predicted in the PAMPA assay, this 
assay cannot determine if a compound interacts with the membrane without crossing it. 
Interactions with lipid membranes can also predict the means of transport in the blood (e.g. 
lipoproteins), or accumulation in fat tissues or organs with high lipid content, such as the 
brain. Liposomes were prepared to investigate if selected analogues could associate with the 
liposome membrane. This laborious method is much more time-consuming than the high-
throughput PAMPA assay, and only three analogues were tested on the liposome model for 
lipid association.  
In order to quantify the amount of analogue associated with the liposomes, a standard curve of 
each analogue was prepared using HPLC (Figure 10). These gave linear trendlines with R2- 
values >0.995 for all three analogues, which was considered a good fit to use to calculate 
amount of analogue in the liposome samples. IM 5 eluted at approximately 4.6 minutes, IM 
20 eluted at approximately 4.0 minutes, and IM 23 eluted at approximately 4.3 minutes. All 
analogues eluted as a single, sharp peak, similar to the chromatogram shown for IM 20 
(Figure 8).  
  
Figure 10. Standard curves were prepared to calculate the concentration of analogue in the liposome 
samples. Standard curves for IM 5 (C), IM 20 (B) and IM 23 (A) were prepared by diluting stock samples 
in MilliQ H2O and acetonitrile. The samples were analysed using the same method as the liposome samples 
(method in section 3.2). The R2-value is >0.995, which is a good fit.  
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In the liposomes incubated with IM 5, the analogue could be observed by HPLC-analysis in 
fraction 14-20 from the gel filtration. It eluted at 4.60 minutes, and the calculated liposome 
association for the combined fractions was 17.2%.  
In the liposomes incubated with IM 20, the analogue could be observed by HPLC-analysis in 
fraction 12-23 from the gel filtration. It eluted with two peaks, one at 3.99 minutes, and the 
other at 4.22 minutes, and the calculated liposome association for the combined fractions was 
3.8%.  
In the liposomes incubated with IM 23, the analogue could be observed by HPLC-analysis in 
fraction 14-21 from the gel filtration. As with the PAMPA assay, IM 23 eluted as several 
peaks with retention times between 3.84 – 5.89 minutes, and the calculated liposome 
association for the combined peaks for the combined liposome fractions was 7.2%.  
The result from all three analogues is summarised in Table 4.  
 
Table 4. Retention time and liposome association  
Analogue Approx. retention time [min] Liposome association [%] 
IM 5 4.60 17.2 
IM 20 3.99 3.8 
IM 23 3.84-5.89 7.2 
 
 
4.1.3. Investigation of the relationship between physiochemical properties, and permeability 
and liposome association 
 
Since the analogues are derivatives of the same parent compound, and thus have structural 
similarities, linear regression was used to investigate if there could be found any relationship 





Figure 11. Analysis of liposome samples by HPLC, see section 3.2 for method. No correlation was 
found between retention time and permeability (A), or between liposome association and permeability 
(B). There was found a strong relationship between retention time and liposome association, as shown 
by the R2-value =0.962 
 
For the liposome samples there was not found any correlation between retention time in the 
HPLC-column and effective permeability calculated from the PAMPA assay, as shown in 
Figure 11A. There was not found any correlation between liposome association and effective 
permeability, as shown in Figure 11B. 
There was however, a strong relationship between retention time of each analogue obtained 
from the standard curve and liposome association (Figure 11C), with an R2-value of 0.962, 
and a Pearson-correlation coefficient of 0.982.  
The effective permeability (logPeff) was calculated from the PAMPA-assay for 42 analogues 
as described in section 3.1, and the calculated log P (clogP) was obtained by in silico-
modelling in ChemDraw as described in section 3.9. Comparing clogP and logPeff showed 





Figure 12. Scatter plot of calculated log P (clogP) values obtained by in silico modelling using 
ChemDraw as described in section 3.9, and effective permeability (logPeff) values calculated from the 
PAMPA assay showed no correlation. 
 
The effective permeability was also compared to the total polar surface area (tPSA) obtained 




Figure 13. Scatter plot comparing the effective permeability (logPeff) calculated from the PAMPA 
assay and total Polar Surface Area (tPSA) obtained by in silico modelling using ChemDraw as 
































Two of the analogues studied in this project (IM 56 and IM 69) contain a piperazine 
substituent (Figure 4). To investigate if this substituent had any effect on the correlation 
between the effective permeability and calculated logP, all analogues containing the 
piperazine- substituent was compared, using the same methods as mentioned previously. No 
correlation was found (Pearson-correlation coefficient = 0.1077). 
 
 
Figure 14. Scatter plot of calculated log P (clogP) values obtained by in silico modelling using 
ChemDraw as described in section 3.9), and effective permeability (logPeff) values calculated from the 

























The piperazine-containing analogues were also investigated for a relationship between 
effective permeability and total polar surface area. The regression analysis performed showed 
an intermediate relationship between the two properties (Pearson-correlation coefficient = 
 -0.8669).  
 
 
Figure 15. Scatter plot comparing effective permeability (logPeff) calculated from the PAMPA assay 
and total Polar Surface Area (tPSA)obtained by in silico modelling using ChemDraw as described in 
















4.1.4. Cytotoxic activity of analogues towards AML cell lines 
 
The WST-1 assay, which measures metabolic activity, was used to assess the toxicity of the 
analogues and calculate their EC50-value for the different cell lines. It showed that DNR was 
more potent than the analogues in both hypoxic and normoxic conditions, and that it was 
more effective in hypoxic conditions than normoxic (EC50-value 0.10 ± 0.08 vs 0.24 ± 0.00). 
The iodinin-analogues also had lower EC50-values in hypoxic conditions for OCI-AML-3 
cells, except from IM 5, but the deviation from the mean was large for the hypoxic EC50-value 
of IM 5 (2.64 ± 0.33 normox. vs 3.79 ± 1.07 hypox.). The results are displayed in Figures 17 
and 18 and compared to other cell lines in Table 5. 
As presented in Figure 16, the result for both normoxic (A) and hypoxic (B) conditions 
showed a correlation between the WST-1 signal and the manual apoptosis count, with a R2-
value of 0.9077 for normoxia, and 0.7132 for hypoxia.  
 
 
Figure 16. Scatter-plot of WST-1 signal and percent apoptosis for all treatments with analogues, as 
described in Figure 17 and 18, show a linear correlation between the WST-1 signal and apoptosis 
count. (A) Result for normoxic conditions. (B) Result for hypoxic conditions.  
 
The individual presentation of the WST-1 signal and percent apoptosis for each analogue is 
shown in Figure 17 (normoxia) and Figure 18 (hypoxia).  
For the normoxia treatment the Pearson-correlation coefficient showed a good fit for all 
drugs, with values below -0.940 for all analogues except from IM 5, which had a correlation 
























































































































































Concentration IM 56 [µM] 
3B
Figure 2. WST-1 viability assay performed on OCI-AML-3 cells in normoxic (19% O2) conditions as described in section 
3.6. WST-1 results (1A-5A) are shown as WST-1 signal of treated cells relative to that of untreated control cells and 
compared to percent apoptosis (1B-5B) for each analogue and DNR. Pearson-correlation coefficient comparing the data 
sets is displayed on the WST-1 signal graph. Note the difference in the x-axis for DNR (5A and 5B). n=2 and whiskers 







































































































































































Concentration DNR [µM] 
5B
Figure 38. WST-1 viability assay performed on OCI-AML-3 cells in hypoxic (1.5% O2) conditions as described in section 
3.6. WST-1 results (1A-5A) are shown as WST-1 signal of treated cells relative to that of untreated control cells and 
compared to percent apoptosis (1B-5B) for each analogue and DNR. Pearson-correlation coefficient comparing the data 
sets is displayed on the WST-1 signal graph. Note the difference in the x-axis for DNR (5A and 5B). n=2 and whiskers 


















The summarised presentation comparing the EC50-values for each analogue in different cell 
lines is shown in Table 5. It shows that the analogues are more potent (have lower EC50-
values) in hypoxic environment than in normoxic environment in the AML-cell lines MOLM-
13 and OCI-AML-3. In the NRK cell line, which represents normal kidney epithelia, the 
analogues are less potent in hypoxic conditions (for IM 5 the value is >50 for both 
conditions).  
The results also show that the analogues are less potent against NRK and H9c2 cells than 
AML cell lines. For DNR the ratio for EC50-values for H9c2 against values for OCI-AML-3 
in normoxic conditions is 4.2, for IM 5 the ratio is >18.9, for IM 20 the ratio is 12.2, for IM 
56 the ratio is 13.4, and for IM 69 the ratio is 7.3.  
 
Table 5. EC50-values [µM] (±SEM) of iodinin-analogues in human AML cell lines (MOLM-13 
and OCI-AML-3) compared to rat kidney epithelial (NRK)- and cardiac myeloblast (H9c2) cell 
lines a. 
 MOLM-13** OCI-AML-3 NRK** H9c2** 
Cpd. Normoxia Hypoxia Normoxia Hypoxia  Normoxia Hypoxia Normox. 
IM 5 2.00 ± 0.07 0.79 ± 0.10 2.64 ± 0.33 3.79 ± 1.07 > 50 >50 >50 
IM 20 0.57 ± 0.06 0.49 ± 0.12 1.23 ± 0.03 0.92 ± 0.28 11.0 ± 1.6 18.0 ± 1.5 15 ± 0.9 
IM 56 1.00 ± 0.06 0.98 ± 0.08 1.94 ± 0.52 1.60 ± 0.86 26.0 ± 2.1 39.0 ± 4.2 26 ± 0.9 
IM 69 0.63 ± 0.05 0.54 ± 0.06 1.28 ± 0.57 1.27 ± 0.54 11.0 ± 11.5 13.0 ± 0.7 9.4 ± 0.55 
DNR   0.24 ± 0.00 0.10 ± 0.08   ~1* 
a. The cells were treated with various doses of the analogues IM 5, IM 20, IM 56 and IM 69, or 
Daunorubicin (DNR) for 24 hours, either in normoxia (19% O2) or hypoxia (1.5% O2), before cell 
viability was assessed by WST-1. The data are based on regression analyses of 2 to 4 experiments and 
are adjusted relative to untreated control cells in each experiment using Equation 5. 
* The EC50-value of DNR in H9c2 cells is estimated from Figure 5 in Myhren et al (2013) (87). 






4.2. Generation of ROS in different cell lines treated with phenazine-analogues 
 
4.2.1. ROS-induced DCF-fluorescence is increased by analogues in MOLM-13 cells 
 
The generation of DCF-fluorescence, which is used as an indicator of ROS-generation, 
increased in MOLM-13 cells treated with the analogues IM 5, IM 69, IM 56 and IM 20 
(Figure 19). The increase appeared dose-dependent for IM 69, IM 56 and IM 20. Treatment 
with DNR did not show an increase in ROS-generation in MOLM-13 cells. IM 20 gave the 
strongest DCF-fluorescence measurements of all concentrations, where 9 µM gave an 
increase of about three times what was observed in the untreated cells (Figure 19 A and B).  
 
 
Figure 19. Iodinin-analogues induce a dose-dependent increase in DCF-signal in MOLM-13 cells. 
MOLM-13 cells were incubated with the indicated doses of IM 5, IM 20, IM 56 or IM 69. The doses of 
daunorubicin (DNR) were 0.05, 0.15 and 0.45 µM, respectively. The generation of ROS (by DCF-
fluorecence) was measured after 60 (A) and 120 (B) minutes. The green column is untreated control 
cells. Two experiments were performed in duplicates; n=4 with standard deviation indicated by 





The generation of DCF-fluorescence was less pronounced in H9c2 compared to MOLM-13 
cells (Figure 20 vs. Figure 19). IM 20 induced an increase, which was proven to be 
statistically significant for the concentration of 9 µM. IM 56 induced a DCF-signal 
comparable to the generation in the untreated cells. IM 5 and IM 69 induced DCF-
fluorescence to a lesser degree compared to untreated cells, and there was a significant 
decrease in DCF-signal for the treatment with 1 and 3 µM of IM 5 and IM 69. Note the 
difference in y-axis in MOLM-13 cells (Figure 19) vs H9c2 cells (Figure 20) (0-4 vs 0-2). 




Figure 4. ROS-generation in H9c2 cells after treatment with phenazine analogues or DNR. H9c2 cells 
were treated with indicated doses of analogue IM 5, IM 69, IM 56, IM 20 or daunorubicin (DNR). The 
doses of daunorubicin (DNR) were 0.05, 0.15 and 0.45 µM, respectively. The generation of ROS (by 
DCF-fluorescence) was measured after 120 (A) and 180 (B) minutes. The green column is untreated 
control cells. Five experiments were performed in duplicates; n=10, with standard deviation indicated 






4.2.2. Generation of DCF-fluorescence in MOLM-13 cells is reduced by the antioxidant N-
acetyl-cysteine (NAC) 
 
Since the cell can utilise antioxidants to protect itself against ROS-induced damage, the 
antioxidant N-acetyl-cysteine (NAC) was used in combination with the analogues on MOLM-
13 cells to see if it induced a reduction in ROS-levels. The result from the experiment showed 
that the DCF fluorescence signal was reduced in the cells treated with a combination of 
analogue and 10 mM NAC compared to the signal from the cells treated only with analogues 
(Figure 21).  
 
 
Figure 5. Co-treatment with NAC causes a significant decrease in analogue-induced ROS-production 
in MOLM-13 cells. The cells were treated with 3 or 9 µM of analogue IM 5, IM 20, IM 56, and IM 69 
and either co-treated with 10 mM NAC or not. The generation of ROS (by DCF fluorescence) was 
measured after 60 (A) and 120 (B) minutes. One experiment was performed in duplicates; n=2 with 





To further investigate if the cells are affected by alterations in their protection against ROS-
damage, MOLM-13 cells were pre-treated with sulfasalazine (SAS) for a WST-assay, as 
described in section 3.6. The results of the WST-1 assay performed showed that the viability 
decreased (lower WST-1 signal) in MOLM-13 cells pre-treated with SAS compared to the 
cells only treated with analogues (Figure 22). Co-treatment with IM 56 and SAS halves the 
EC50-value based on WST-1 signal to ~2 µM, relative to treatment with IM 56 only (Figure 
22 A). Co-treatment with IM 20 and SAS reduces the EC50-value from ~1.7 µM to 1.2 µM 




Figure 22. Pre-treatment with sulfasalazine (SAS) prior to treatment with analogues causes a 
decrease in metabolic activity MOLM-13 cells, relative to cells treated with an analogue only. Cells 
were seeded in 96-well plates as 10 000 cells/well. Half of the cells were pre-treated with 250 µM 
sulfasalazine (SAS) for 24 hours. SAS was removed, and the cells were incubated the indicated doses 
of IM 56 (A), IM 20 (B) or IM 5 (C) for 24 hours and analysed by WST-1 assay. Two experiments were 
performed in duplicates; n=4 with stdev. indicated by whiskers. Results from WST-1 assay was 
confirmed by counting living and apoptotic/dead cells by fixing cells in a 2% buffered formaldehyde 





We suspected that the analogues might affect the respiratory chain in the mitochondria of the 
cells by ROS-induction as a part of its mechanism of action. To investigate this, MOLM-13 
cells were co-treated with the analogues and an inhibitor of complex I, Phenformin (31, 72) to 
investigate if any additional effect could be observed (Figure 23). Co-treatment with IM 56 
and 5 mM phenformin increased the viability (reduced apoptosis) for IM 56-doses between 4 
and 13 µM relative to treatment with IM 56 only (Figure 23 A). The viability was decreased 
for co-treatment with 5 mM phenformin and analogue IM 20 (Figure 23 B) and IM 5 (Figure 
23 C) relative to treatment of IM 20 and IM 5 only.  
 
 
Figure 23.6 Phenformin affects the viability of analogue-induced apoptosis in MOLM-13 cells. 
MOLM-13 cells were treated with the indicated concentrations of analogue IM 56 (A), IM 20 (B) and 
IM 5 (C), and half of them were in addition treated with 5 mM phenformin for 4 hours before a 2% 
buffered formaldehyde solution added Hoechst 33342 staining was added to each well. Percent 
apoptosis was determined by manual counting of cells and is shown relative to apoptosis in untreated 







4.3. Investigation of the cell signalling pathways susceptible to ROS-generation  
 
As the induction of ROS-generation appeared to be a part of the mechanism of action for the 
iodinin analogues (Figure 21 and 23), we wanted to see if there was a change in the proteins 
known to be susceptible to alterations of ROS-levels in the cell.  
As shown in Figure 24, the amount of phosphorylated AMPKα relative to total AMPKα is 
decreased in MOLM-13 cells treated with IM 5 and IM 56, with the most pronounced 
reduction in the cells treated with IM 56 for 3 hours. The amount of pAMPKα was increased 
in the cells treated with phenformin, in agreement with other studies (70). We also noted that 
the total amount of AMKPα decreased in cells treated with high concentrations of IM 56, but 




Figure 24. Iodinin and its analogue IM 56 cause a decrease in phosphorylation of AMPKΑ. MOLM-
13 cells were incubated with IM 56 for 3 and 6 hours, at a concentration of 3 and 9 µM, or with IM 5 
for 6 hours at the same concentrations. Two cell conditions were treated with 5 mM phenformin for 1 
and 3 hours. Samples from each condition were transferred to fix-solution and percent apoptosis was 
assessed as described in section 3.6. Western blotting was performed as described in section 3.8, and 
the membrane was incubated with antibodies for pAMPKα and AMPKα, with β-actin as loading 
control (see Table 3). The graph shows amount of phosphorylated AMPKα relative to total AMPKα in 




The translation initiation factor 4E-binding protein (4E-BP) is placed downstream from 
AMPK and mTOR and is important to regulate protein synthesis (16). The amount of 
phosphorylated 4E-BP increases relative to the total 4E-BP in all samples (Figure 25). 
Although there was an increase in the phosphorylated form of 4E-BP relative to the total 
protein when MOLM13 cells were treated with 9 µM IM 56 for either 3 or 6 hours, the 
protein was almost totally absent compared to β-actin (Figure 25). 
 
 
 Figure 75. Iodinin and its analogue IM 56 affect 4E-BP expression in MOLM-13 cells. Results from 
incubating the same membrane as in Figure 24. The membrane was incubated with antibodies for 
phosphorylated 4E-BP and total 4E-BP, with β-actin as loading control (see Table 3). The graph show 
amount of phosphorylated 4E-BP relative to amount of total 4E-BP in treated cells relative to an 











In this study we have provided experimental documentation on possible lead candidates for 
AML therapy, based on analogues derived from the previously discovered hit compound 
phenazine 5,10-dioxide (iodinin). Several analogues had already been tested for effect in one 
AML cell line and two normal cell lines, and the findings of physiochemical properties and 
biological activity presented herein has led to the selection of analogue IM 56 as the most 
promising lead. This conclusion is based on the analogue’s increased cytotoxicity to AML 
cell lines relative to normal cell lines, and suitable results from the permeability assay.  
The first property to be investigated was the analogue’s ability to cross biological membranes. 
The permeability assay can explain why some of the analogues show more desirable effects in 
cell assays than others and can also predict how the analogues will interact with cell 
membranes or other lipid structures in the body. The analogues focused on in this project 
represented three of the four categories of permeability (Figure 7). The parent compound, IM 
5, was classified as an intermediate permeability compound, the analogues IM 20 and IM 69 
as high permeability compounds, and IM 56 as a low permeability compound.  
Of all of the analogues, IM 20 was the most potent against the AML cell lines (Table 3) and 
the PAMPA assay showed that IM 20 had high ability to passively diffuse across a 
phospholipid membrane (Figure 7). It will therefore rapidly reach the critical intracellular 
concentration needed to disturb the cell signalling and initiate the apoptotic process. This 
implicates that the ability an analogue has to cross cell membranes can affect its ability to 
induce a cytotoxic effect in cells.  
The rapid diffusion across cell membranes can also be a negative feature, as the analogue will 
diffuse rapidly into normal cells as well. As shown in Table 3, analogues IM 20 and IM 69, 
which both were classified as high permeable analogues, also have the highest potency 
against the cell lines representing normal tissue, namely the NRK epithelial cells and H9c2 
cardiomyoblasts. Since cardiotoxicity is a common and severe side effect of the standard 
AML treatment utilising anthracyclines (e.g. Daunorubicin), a desirable effect of any new 
compound against AML would be to not affect heart function negatively. 
One issue with IM 20 which can hamper its further development as a drug candidate, is the 
substituents. As shown in Figure 4 IM 20 has an ester moiety as its R2 substituent. Esters are 
rapidly hydrolysed, and if this substituent is cleaved off, the resulting molecule is identical to 
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analogue IM 18 (structure shown in Supporting Table 2). As shown in Figure 7, the PAMPA 
assay classifies IM 18 as an impermeable compound, and Viktorsson et al. has shown that the 
EC50 value of IM 18 in MOLM-13 cells is >50 µM in both normoxia and hypoxia (35) 
(Supporting Table 2). It is likely that IM 20 will be converted into IM 18 before it reaches 
AML cells, especially if administered orally, as it would have to withstand hydrolysation both 
in the gastrointestinal tract, and the first pass metabolism in the epithelial cells in the intestine 
and in the liver.  
Another issue with IM 20 is, as mentioned above, that it is more potent against H9c2 cells 
than e.g. IM 56 (Table 5). This could possibly be explained by its rapid diffusion, but it could 
also be a result of a degradation of IM 20, if the degradation products are cytotoxic or the 
reaction itself induce cytotoxicity, for instance by generation of ROS.  
Even though IM 56 has a higher cytotoxic effect on AML cell lines than IM 5 itself, it was 
found to have a low permeability in the PAPMA assay, while IM 5 had an intermediate 
permeability (Figure 7).  
The low permeability of IM 56 might explain why it is less potent than IM 20 and IM 69 in 
the viability assay performed on OCI-AML-3 cells (Table 5). As IM 56 also showed less 
toxicity towards the normal cell lines, it is possible to hypothesise that the potency of the high 
permeability compounds makes the therapeutic window of IM 20 and IM 69 too narrow to 
safely use them as drugs. The parent compound, IM 5, showed an effective permeability 
similar to IM 56 (Figure 7), but showed less toxicity against the AML cell lines than IM 56 
(Table 5).  
The analogue IM 23 was used as a negative control in the liposome assay, as it had shown 
poor activity in previous cell assays (EC50 = 50 ± 0.4 µM in MOLM-13 in normoxic 
conditions). HPLC- analysis of pure IM 23 diluted in acetonitrile and milliQ H2O for the 
standard curve used for the liposome assay gave a chromatogram which resembled the 
chromatogram for IM 20, shown in Figure 8. However, the analysis of the samples from the 
donor and acceptor well of IM 23 in the PAMPA assay gave a different result, as shown in 
Figure 9. The sample from the donor well eluted as several peaks, and it was not possible to 
separate the peaks. The chromatogram of the acceptor well showed that only small amounts of 
the analogue had been able to diffuse through the phospholipid membrane, and calculations 
from the assay classified IM 23 as impermeable (Figure 7). The structures of IM 20 and IM 
23 (Figure 4 and 26 respectively), differ only by that the carbon before the carbonyl-group in 
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the R2 substituent has been removed in the structure of IM 23, but this difference clearly has a 
significant impact on the physiochemical properties of the analogue.  
A possible explanation to the different 
behaviour in the PAMPA and cytotoxicity assay 
is that IM 23 forms complexes when diluted in 
phosphate buffered saline (PBS). PBS contains 
Na+ and K+ that can form a complex with IM 23, 
as proposed in Figure 26. This is similar to the 
complex formation known to happen between 
the tetracycline class of antibiotics and metal 
ions (88). A possible reason to why this happens 
in IM 23 and not in IM 20 is that the carbon 
atom missing in IM 23 shields the electrons in 
the ring-structure from being pulled by the 
carbonyl unit and therefore avoids 
destabilisation of the rings.  
The possible complex(es) formed are either to 
large or charged to be able to cross the 
phospholipid membrane in the PAMPA assay, as shown by the minute amounts of IM 23 
present in the acceptor well of IM 23 (Figure 9). If IM 23 forms complexes in a simple buffer 
like PBS, it is likely to do so also in cell culture medium, which can explain why it is not 
active towards either cell line investigated. Moreover, body fluids like the blood contains high 
amounts of cationic metal ions and complexation of IM 23 is likely to occur. The PAMPA 
and HPLC-analyses thus explains why IM 23 is not active against AML cells, although it is 
very similar to the active compound IM 20. 
Although the analogues’ ability to cross membranes is predicted in the PAMPA assay, it does 
not allow us to determine if an analogue is associated with the membrane without crossing it. 
The liposome assay (section 4.1.2-3) was performed to investigate to what extent the 
analogues could be internalised in liposomes and their membrane. The results from the 
liposome assay can be interpreted as a permeability assay, but liposomes are also an 
administration formulation for anti-cancer drugs (89). IM 5 showed high liposome association 
(17.2%) but low loading efficiency, and it is not clear if the analogue is internalised into the 
liposomes or adsorbed onto the surface. This needs to be clarified before a possible liposomal 
Figure 26. Proposed mechanism for complex-formation 




formulation of IM 5 can be tested for biological activity. If it is eligible, a future drug 
formulation would be to administer the analogue encapsulated in liposomes, which ideally has 
a high affinity to target AML cells.  
The permeability assay gives information about how much of the compound crossed over to 
the acceptor plate, relative to the donor plate, whereas in the liposome assay it is not possible 
to differ between how much compound that have crossed completely over the membrane, and 
how much of the compound that is associated with the membrane.  
This show a significant difference between the two assays; the artificial membrane assay will 
only give information about the drugs that cross the membrane into the acceptor plate, 
whereas the liposome assay also includes the compounds that interacts with the membrane 
without crossing, such as insertion between the phospholipids. This can be of importance 
when studying new compounds, where the mechanism of action is unknown. If the compound 
does not cross the membrane, but interacts with cell membranes, like IM 23, it can associate 
with the cell membrane of blood cells, blood plates and lipoproteins. This can give 
information on how a drug is transported in the blood, and further its biodistribution in the 
body. For example, the ester group of IM 20 is likely to degrade into the carboxylic acid 
moiety of IM 18 (Supporting Table 2), and will thus be charged in the blood, and susceptible 
for renal excretion. More lipophilic drugs, like IM 56 and IM 69, will bind to lipoproteins and 
be distributed into adipose and hepatic tissue. This can lengthen the drugs half-life in the body 
compared to hydrophilic drugs, and it will be more susceptible to hepatic clearance (37). 
It is important to consider that both assays only show passive diffusion over the membrane, 
and that the drug can be internalized in a cell trough active transport as well. In the PAMPA 
assay, Daunorubicin was classified as an impermeable compound, but its high activity in cell 
assays suggest an active transport over the cell membrane, which also has been proven in 
previous literature (44). It is also possible that the analogues could be subjects of active 
transport, which will alter their rate of internalisation in a cell. The permeability of IM 56 was 
classified as low, but the cytotoxicity is comparable to that of IM 20 (Table 5). This could 
mean that IM 56 is in fact more potent than IM 20, but is unable to reach the inside of the cell 
to the same extent as IM 20. This theory is possible to test by performing an assay 
microinjecting IM 56 into the cell.  
There was found no correlation between the effective permeability and clogP (Figure 12) or 
tPSA (Figure 13) for all analogues, or between logPeff and clogP for the analogues containing 
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the piperazine unit like IM 56 (Figure 14). There was a correlation between logPeff and tPSA 
for the piperazine-containing analogues (Figure 15). One can question the reliability of these 
findings, since the in silico prediction of chemical properties of structures like phenazines, 
where the distribution of charge between the atoms is not fixed, tends to be difficult to handle 
for computer software. Drugs belonging to the phenothiazine class, which has a similar three-
ring system as phenazines, where one of the N-atoms is changed to a S-atom, has been 
referred to as “heavy outliers” in literature comparing experimental and calculated log P (90). 
A possible improvement of the prediction could have been gained by using the distribution 
coefficient, log D, instead of the partition coefficient, clog P. Log D is the overall ratio of the 
drug partitioned between the organic and aqueous phase, describing a drug’s lipophilicity at a 
fixed pH (91). The distribution of charge in a molecule changes by changing pH, and thus 
choosing a fixed pH (e.g. 7.4) could make it easier to predict the chemical properties.  
In this thesis, two different methods were used for assessment of cell viability. Comparing 
WST-1 results with results from manual counting of apoptotic cells (Figure 17 and 18), show 
good correlation, which support the use of WST-1 as a satisfactory method to assess viability 
for these analogues. In most cases, the EC50- value was higher when measuring metabolic 
activity compared to counting apoptotic cells (Figures 17 1-5A vs. 17 1-5B for normoxia and 
Figures 18 1-5A vs. 18 1-5B for hypoxia). This can be explained by that some of the pre-
apoptotic cells still have intact mitochondria and metabolic activity which is registered by the 
WST-1 assay, but when studied in a microscope their nuclei appear apoptotic. Moreover, 
apoptotic and other cell deaths are associated with increased ROS levels in the cytoplasm, 
which can contribute to the conversion of WST-1 to the formazan product (92). 
An important property of a drug is its therapeutic window. Ideally, this should be as large as 
possible to ensure good therapeutic effect without unacceptable side-effects. For 
anthracyclines, it is relevant to compare its effect on AML-cells with that on cells from the 
heart.  
The viability studies performed on OCI-AML-3 cells, as well as previous findings (35), 
showed that daunorubicin (DNR) is more potent than the phenazine analogues (Table 5). 
However, daunorubicin has a high toxicity towards cardiomyoblasts compared to the 
analogues. For IM 5 and 56, there is a larger difference in EC50 between AML cells and 
cardiomyoblasts compared to daunorubicin (Table 5). This points towards that IM 5 or IM 56 
can be used for AML with less chance for cardiac failure. 
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As shown in Table 5, the analogues are in general more potent in hypoxic conditions than in 
normoxic conditions. Tumours tend to be less perfused than normal tissue, and therefore have 
a hypoxic environment. AML is a cancer that does not form solid tumours, but there is 
evidence that the bone marrow has niches where there is a hypoxic environment, and that the 
AML cells residing here give rise to relapses (93, 94). Drugs with increased activity in 
hypoxic conditions will thus act stronger in the hypoxic niches where resistant AML cells 
reside, but less on the normal tissues, which also are sensitive to cytostatics, like the heart, 
peripheral blood, and intestine.  
For the highest doses of analogues, especially with IM 20, it was sometimes challenging to 
differentiate between normal and apoptotic nuclei in the microscope. One explanation can be 
that cells die very rapidly, such that the classic signs of apoptosis do not have time to develop. 
This has previously been demonstrated in AML cell lines treated with anthracyclines and a 
protein synthesis inhibitor (62).  
Since as a possible mechanism of action for phenazine class compounds involves the 
mitochondrial respiratory chain (35), the detection of generation of reactive oxygen species 
(ROS) is central in order to understand the mechanism, and also to be able to select a lead 
candidate.  
The DCF-DA ROS detecting assay performed on MOLM-13 cells (Figure 19) showed an 
increase in DCF-signal relative to the control induced by all analogues tested, although only 
the highest concentration of IM 20 was proven give significant higher DCF-signal. The 
increase was largest for IM 20 compared to the other analogues, which also supports the 
previous findings that the analogue permeates the cell rapidly and is highly potent. The 
increase in DCF-signal appears to be dose dependent, and does not increase over time, as the 
DCF-signal is similar for both 60 (Figure 19 A) and 120 minutes (Figure 19 B). IM 69 
induced a lower increase in DCF-signal than IM 20, but also showed no increase over time. 
Since IM 20 and IM 69 rapidly diffuse across membranes (Figure 7), it is likely that they 
reach the necessary concentration to generate maximum ROS production before the first 
recording after 60 minutes.  
On the other hand, the generation of DCF-signal induced by IM 56 increased with higher 
concentrations of IM 56, and the signal is higher after 120 minutes (Figure 19 A) than after 60 
minutes (Figure 19 B). The delay in ROS generation compared to IM 20 can be explained by 
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that IM 56 has lower permeability (Figure 7), and thus needs more time in order to reach a 
critical intracellular concentration. 
The generation of DCF-signal induced by IM 5 appears to be quite similar to IM 69, with 
higher DCF-signal at 60 minutes (Figure 19 A) relatively to 120 minutes (Figure 19 B). The 
permeability assay classifies IM 5 as intermediate to low permeability (Figure 7), which can 
explain why its effect is in between that of IM 56 and IM 69. The EC50-values presented in 
Table 5 show that IM 5 is less potent than the other analogues. This might explain why there 
appears to be a leap in the DCF-signal induced by IM 5 from 1 and 3 µM to 9 µM (Figure 
19). 
The H9c2 cells (Figure 20) show a less pronounced generation of ROS relative to MOLM-13 
cells (Figure 19). IM 20 induces the highest DCF-signal, most pronounced at a concentration 
of 9 µM, which is supported by the EC50- values showing IM 20 is more potent in H9c2 cells 
relative to IM 5 and IM 56 (Table 5). The DCF-signal induced by IM 5 is low, which also is 
reflected by the EC50 -value (>50 in H9c2 cells). Surprisingly, DNR did not induce an 
increase in the DCF-signal relative to the control cells. A possible explanation could be that 
DNR needs to be transported into the cell, and that it reaches maximum level on a later time-
point than the last reading at 180 minutes. IM 69 was also expected to increase ROS based on 
the viability assays, but it showed a decrease in DCF-signal, which was proven to be 
statistically significant for 1 µM and 3 µM after 120 minutes (Figure 20A). The signal 
increased after 180 minutes (Figure 20 B), which suggests that the induction of ROS in H9c2 
cells by IM 69 is slower than IM 20, even if they are both highly permeable. 
To further investigate the effect of ROS-generation in the cells we tried to manipulate the 
cells mechanisms against ROS-induced damage in two different ways. First, by treating the 
cells with an anti-oxidant to see if this could lower the ROS production, and secondly by pre-
treating the cells with a drug that depletes them of one of their natural antioxidants.  
The treatment of MOLM-13 cells with a combination of the antioxidant N-acetyl-cysteine 
(NAC) led to a statistically significant overall decrease in DCF-signal relative to the DCF-
signal from cells treated only with analogues (Figure 21).  
Pre-treating MOLM-13 cells with sulfasalazine (SAS) was hypothesised to reduce the 
viability of cells, since it is known to deplete the cell of cysteine, a pre-cursor to the 
antioxidant glutathione, and thus sensitise the cells to ROS-meditated death (95). The 
reduction in viability seen with for instance IM 56 (Figure 22 A) supports that glutathione 
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could act as a protector to apoptosis induced by phenazine analogues. However, the 
concentrations of analogues used in this experiment were not sufficient for reducing the 
viability to zero, and further work should also observe the ROS-production by DCF-DA assay 
in cells co-treated with SAS and the phenazine analogues. Still, we can conclude that ROS 
generation is pivotal in AML cell death generated by phenazine-analogues, as demonstrated 
by the reduced DCF-signal in cells treated with NAC, and increased cell death in cells with 
blocked uptake of glutathione precursor. 
Treating the cells with IM 5 and IM 56 induced a reduction in the levels of phosphorylated 
AMP-activated protein kinase (AMPK) compared to the total level of AMPK (Figure 24). 
This is expected to lead to an increase in mTOR activation, followed by an increase in 
mTOR-mediated phosphorylation of 4E-BP. We detected an increase in phosphorylated 4E-
BP relative to the total protein for all treatments used (Figure 25). Treatment with 9 µM IM 
56 for 3 or 6 hours led to an almost complete degradation of the protein. This might be caused 
by the high percentage of apoptotic cells in these samples (61.8% and 68.9%).  
The drug phenformin (PhF) is known to inhibit complex I of the respiratory chain in the 
mitochondria and this is also a location where the cell generates ROS (31, 72). In the western 
blot it was used as a positive control for phosphorylation of AMPK. As the treatment with IM 
5 and IM 56 led to a reduction of AMPK, a combination treatment was tested (Figure 23) to 
investigate if the opposite effects would affect the viability. The combination treatment 
resulted in more apoptosis for analogue IM 5 (Figure 23 C) and IM 20 (Figure 23 B), but 
surprisingly not for IM 56 (Figure 23 A), where the combination treatment decreased the 
apoptosis. This might suggest that IM 56 have a different mechanism of action compared to 
IM 5 and IM 20, which also can be indicated by the results from western blotting for 4E-BP 
(Figure 25). Here, the highest concentration of IM 56 (9 µM), almost completely knocked 
down the expression of 4E-BP. The total AMPK-expression is also altered for this 
concentration, (Figure 24), which might support this theory. This additional effect could be 
caused by the piperazine R1-substituent (Figure 4), which is absent on both IM 5 and IM 20. If 
this is the case, similar results should be obtained with IM 69, since it has the same piperazine 
substituent as IM 56 (Figure 4). 
Interestingly, treatment of cells with phenformin affected phosphorylation of 4E-BP 
oppositely compared to what was seen with the analogues; the strong activation of AMPK by 
phenformin (Figure 24), would be expected to decrease the phosphorylation of 4E-BP, but as 
shown in Figure 25, this treatment lead to an increase.  
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Protein kinase B (AKT) (Supporting Figure 2) protein S6 kinase (P70S6K) (Supporting 
Figure 1) were not changed relative to the total protein, but the level of total protein was 
lowered with all treatments. However, the quality of these blots is not sufficient to draw final 
conclusions. The total protein was lowest in two of the lanes with highest percent apoptosis 
(lane 4 and 7), but not for lane 5, which also had a high percentage of apoptosis. Taken 
together, the western blots showed that both 4E-BP, AKT and P70S6K is degraded compared 
to β-actin. This points towards degradation of these proteins, but not degradation of 
cytoskeletal components, either by apoptosis initiated by caspase cleavage, or by lysosomal 
degradation by autophagy. 
The first report on iodinin and AML showed cleavage of procaspase 9 into active caspase 9 
(87). In order to find if autophagic mechanisms are activated, specific markers like LC3 
should be investigated. The dephosphorylation of AMPK is generally associated with 
impaired autophagic function (96). In order to conclude further from the western blots with 
AKT and P70S6K, they should be repeated to ensure that protein loading is similar. 
Furthermore, to exclude cell death mediated protein degradation, lower concentrations of 
cytotoxic agents must be used. 
Future studies should also investigation of mTOR, from the same cell lysate preparation in 
order to find if this is the mediator of down-stream effects of AMPK dephosphorylation. If 
this is the case, a combination treatment with an mTOR inhibitor and for instance IM 56 could 










6. Concluding remarks 
 
The main aim of this master thesis was to investigate the biological activity and 
physiochemical properties of analogues of from the phenazine 5,10-dioxide, iodinin, to be 
able to choose one analogue with superior drug properties for further clinical studies. The 
information obtained in this work, together with previous findings, led to the selection of IM 
56 as the most promising candidate for future drug development.  
This conclusion is based on the favourable results shown for IM 56 over the other analogues. 
Most importantly, it showed enhanced cytotoxic effect towards AML cell lines compared to 
the parent compound, IM 5. The potency of IM 56 is lower against normal cell lines 
compared to the other analogues, as well as the current standard treatment, daunorubicin. It 
induced an increase of ROS-generation in MOLM-13 cells, but not in cardiomyoblasts.  
The results of the investigation of the physiochemical properties using a permeability assay 
gave valuable information regarding the analogues, providing a partial explanation of the 
results shown in the cytotoxicity assays. 
The analogue IM 20 also showed high cytotoxic effects towards AML cell lines, and could 
have been chosen as a drug lead, but there are some drawbacks regarding this analogue. The 
high cytotoxic effect is also shown towards the normal cell lines, and it induced high levels of 
ROS in cardiomyoblasts. It is highly permeable over phospholipid membranes, which 
increases the risk of undesirable side-effects. Lastly, IM 20 is likely to be susceptible to 
unwanted degradation to IM 18 in the body. IM 18 was shown to be inactive and 
impermeable.  
In total, the abovementioned findings make IM 56 a better choice for a drug lead, as it is less 
likely to have severe side-effects compared to the more potent analogue IM 20.  
The molecular mechanism of action was not found during the work for this thesis, and further 
studies should be performed. The results suggest that the mechanism of action includes 
involvement of ROS generation and modulation of the cell signalling pathways connected to 
AMPK. Both down-stream and up-stream factors of AMPK should be further studied to 
confirm this.  
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7. Further studies 
 
Development of the analogue IM 56 into a marketable drug would require several steps, 
starting with further pre-clinical studies in systems that resembles the complexity of the body. 
Since a key point against the standard treatment with daunorubicin is cardiotoxicity, studies 
should be performed to reveal any possible negative effect of IM 56 in an intact heart model. 
To pinpoint the molecular mechanism of action further studies should focus on investigation 
of how the analogue induces generation of ROS and how this affects the cell. A possible 
method to study the link between ROS-generation and the mitochondrial respiratory chain is 
utilising an assay that monitors the oxygen consumption in the mitochondria when treating the 
cell with the analogue. Anthracyclines induce DNA-damage by intercalation, and possible 
DNA-intercalation with the analogues should be investigated by direct DNA-drug interaction 
studies. 
Since we have selected a lead compound for drug development it is natural to continue in vivo 
pharmacokinetic and pharmacodynamic studies, and thereafter efficacy studies in an animal 
model for AML. Preferably, the first efficacy study should be a model where MOLM-13 cells 
can be used, for instance by xenografts in mice.  
After toxicity studies, the most suitable way to administer the analogue as a drug should 
investigated. An oral route of administration would be preferred, but intravenous injections or 
infusions are commonly used in cancer therapy and could be chosen, depending on the dose 
regimen developed for the compound.   
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Supporting Figure 1. Western blot for pP70S6K and P70S6K. MOLM-13 cells were incubated with IM 
56, IM 5 and DMSO for 4 hours, at a concentration of 2 and 4 µM (IM 56), or with IM 5 or DMSO at 
a concentration of 10 µM. Duplicates of the drug-conditions were co-treated with 5 mM phenformin. 
Samples from each condition were transferred to fix-solution and percent apoptosis was assessed as 
described in section 3.6. Western blotting was performed as described in section 3.8, and the 
membrane was incubated with antibodies for pP70S6K and P70S6K, with β-actin as loading control 
(see Table 3). The bottom graph shows amount of phosphorylated P70S6K relative to total P70S6K in 
treated cells relative to an untreated control. The upper graph show amount of total P70S6K. The 





Supporting Figure 2. Western blot for pAKT and AKT. MOLM-13 cells were incubated with IM 56, IM 
5 and DMSO for 4 hours, at a concentration of 2 and 4 µM (IM 56), or with IM 5 or DMSO at a 
concentration of 10 µM. Duplicates of the drug-conditions were co-treated with 5 mM phenformin. 
Samples from each condition were transferred to fix-solution and percent apoptosis was assessed as 
described in section 3.6. Western blotting was performed as described in section 3.8, and the 
membrane was incubated with antibodies for pAKT and AKT, with β-actin as loading control (see 
Table 3). The bottom graph shows amount of phosphorylated AKT relative to total AKT in treated 
cells relative to an untreated control. The upper graph show amount of total AKT. The table show 
percent apoptosis relative to untreated control.  
 
 
Supporting Figure 3. Example of quantification of protein expression in western blots. Performed 
using ImageJ Analyze>gel tool. Numbers 1-9 indicate area corresponding to the intensity of the 






Supporting Table 1. 
  
Structures and EC50-values for phenazine analogues. Table provided by Elvar Örn Viktorsson, 






































1.4 ± 0.30 0.77 ± 
0.13 
77 ± 11 
(n=2) 
76 ± 14 
(n=2) 







95 ± 8* 22 ± 2* >100* 
(n=3) 









2.9 ± 0.34 2.4 ± 
0.16 
53 ± 1.5 
(n=2) 
53 ± 0.0 
(n=2) 











11 ± 1.6 
(n=3) 
18 ± 1.5 
(n=3) 

















































36 ± 0.1 
(n=5) 
 
22 ± 2.8 
(n=4) 




50 ± 0.4 
(n=4) 
 
66 ± 2.2 
(n=4) 






























53 ± 2.0 
(n=2) 
 
































































































































































































































































































































































44 IM66  
2.8 ± 0.25 
 (n=6) 
 























n.d. n.d. n.d. 
 
48 IM68  
8.3 ± 0.78 
 (n=6) 
 



































1.3 ± 0.2 
(n=3) 
 
51 IM75  










































9.4 ± 0.55 
 
53 IM83  



















2.3 ± 0.05 
(n=2) 
 



































































































































































n.d. n.d. n.d. 
 
- 
IM41 - - - - - 
 
- 
IM61 - - - - - 
 
- 




Supporting Table 2. 
 
Supporting Table 2. Structures and EC50-values of phenazine analogues not provided in Supporting 
Table 1. Data from Viktorsson et al (2017, Table 1). 
 IC50 [µM] 
Structure Name  Cpd no.: Normoxia Hypoxia  
 
IM11 12 147 ± 17* 22 ± 9.1 
 
IM2 14 276 ± 17 39 ± 16 
 
IM18 19 54 ± 13 61 ± 8 
 
 
